Novo Nordisk shares plunge on outlook warning as Mounjaro rival races ahead
Wegovy and Ozempic maker Novo Nordisk forecast plunging sales and earnings in 2026, which saw the Danish drugmaker’s shares plummet by nearly a fifth.
Evening Standard ·